JP2017519020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519020A5 JP2017519020A5 JP2016574359A JP2016574359A JP2017519020A5 JP 2017519020 A5 JP2017519020 A5 JP 2017519020A5 JP 2016574359 A JP2016574359 A JP 2016574359A JP 2016574359 A JP2016574359 A JP 2016574359A JP 2017519020 A5 JP2017519020 A5 JP 2017519020A5
- Authority
- JP
- Japan
- Prior art keywords
- reperfusion injury
- therapeutic
- prophylactic agent
- agent according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 206010063837 Reperfusion injury Diseases 0.000 claims 12
- 230000000069 prophylactic effect Effects 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 6
- 102000019259 Succinate Dehydrogenase Human genes 0.000 claims 6
- 108010012901 Succinate Dehydrogenase Proteins 0.000 claims 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000001384 succinic acid Substances 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 210000003771 C cell Anatomy 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims 1
- 208000014139 Retinal vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- OREAFAJWWJHCOT-UHFFFAOYSA-N dimethylmalonic acid Chemical compound OC(=O)C(C)(C)C(O)=O OREAFAJWWJHCOT-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000002283 elective surgery Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000013037 reversible inhibitor Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411937.4A GB201411937D0 (en) | 2014-07-03 | 2014-07-03 | Succinate dehydrogenase inhibitors (SDH's) |
| GB1411937.4 | 2014-07-03 | ||
| PCT/GB2015/051949 WO2016001686A1 (en) | 2014-07-03 | 2015-07-03 | SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519020A JP2017519020A (ja) | 2017-07-13 |
| JP2017519020A5 true JP2017519020A5 (enExample) | 2018-07-19 |
Family
ID=51410633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574359A Pending JP2017519020A (ja) | 2014-07-03 | 2015-07-03 | コハク酸脱水素酵素阻害剤（ＳＤＨｉ’ｓ） |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10603298B2 (enExample) |
| EP (1) | EP3164126B1 (enExample) |
| JP (1) | JP2017519020A (enExample) |
| CN (1) | CN106714793B (enExample) |
| AU (1) | AU2015282424A1 (enExample) |
| CA (1) | CA2953709A1 (enExample) |
| GB (1) | GB201411937D0 (enExample) |
| SG (1) | SG11201610588UA (enExample) |
| WO (1) | WO2016001686A1 (enExample) |
| ZA (1) | ZA201608844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148550A1 (en) * | 2017-02-10 | 2018-08-16 | Health Research, Inc. | Targeting mitochondrial complex ii to reduce effects of chronic hypoxia |
| WO2019139831A1 (en) * | 2018-01-10 | 2019-07-18 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate |
| WO2020041470A1 (en) * | 2018-08-21 | 2020-02-27 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors |
| CN109793760B (zh) * | 2019-02-13 | 2022-07-19 | 中国人民解放军总医院 | 琥珀酸弧菌属在预防或治疗高原病药物中的用途 |
| GB201918022D0 (en) * | 2019-12-09 | 2020-01-22 | Cambridge Entpr Ltd | Treatment or prevention of Ischaemic Stroke Reperfusion Injury |
| US11813239B2 (en) * | 2020-02-18 | 2023-11-14 | Wisconsin Alumni Research Foundation | Compositions and methods for improving cardiac structure and/or function |
| GB202108594D0 (en) | 2021-06-16 | 2021-07-28 | Cambridge Entpr Ltd | Treatment or prevention of ischaemia reperfusion injury |
| WO2025125766A1 (en) | 2023-12-12 | 2025-06-19 | Cambridge Enterprise Limited | Treatment or prevention of ischaemia reperfusion injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1032403B1 (en) | 1997-10-24 | 2012-05-02 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| US20070173545A1 (en) * | 2003-11-07 | 2007-07-26 | Ajay Verma | Activation of hypoxia-inducible gene expression |
| ES2391662T3 (es) | 2006-09-28 | 2012-11-28 | Medical Research Council | Donadores de óxido nítrico de tionitrílo de trifenilfosfonio |
| WO2011156181A1 (en) * | 2010-06-08 | 2011-12-15 | Montefiore Medical Center | Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins |
| WO2013152193A2 (en) * | 2012-04-04 | 2013-10-10 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating proliferative disorders with malate or derivatives thereof |
| US20140128352A1 (en) * | 2012-09-20 | 2014-05-08 | Buck Institute For Research On Aging | Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production |
| WO2014179187A1 (en) * | 2013-04-29 | 2014-11-06 | Montefiore Medical Center | Methods and compositions for preventing and treating electrophile-mediated toxicities |
-
2014
- 2014-07-03 GB GBGB1411937.4A patent/GB201411937D0/en not_active Ceased
-
2015
- 2015-07-03 AU AU2015282424A patent/AU2015282424A1/en not_active Abandoned
- 2015-07-03 CN CN201580035346.8A patent/CN106714793B/zh not_active Expired - Fee Related
- 2015-07-03 US US15/322,939 patent/US10603298B2/en active Active
- 2015-07-03 SG SG11201610588UA patent/SG11201610588UA/en unknown
- 2015-07-03 JP JP2016574359A patent/JP2017519020A/ja active Pending
- 2015-07-03 WO PCT/GB2015/051949 patent/WO2016001686A1/en not_active Ceased
- 2015-07-03 CA CA2953709A patent/CA2953709A1/en not_active Abandoned
- 2015-07-03 EP EP15736028.0A patent/EP3164126B1/en active Active
-
2016
- 2016-12-21 ZA ZA2016/08844A patent/ZA201608844B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519020A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2018516963A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2014077003A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2012508215A5 (enExample) | ||
| JP2017520527A5 (enExample) | ||
| JP2016512227A5 (enExample) | ||
| JP2015164972A5 (enExample) | ||
| JP2017518360A5 (enExample) | ||
| FI3562487T3 (fi) | Metalloentsyymi-inhibiittoriyhdisteitä | |
| IL312296A (en) | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART | |
| EA201990664A1 (ru) | Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма | |
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| JP2012525358A5 (enExample) | ||
| JP2013523739A5 (enExample) | ||
| JP2015517514A5 (enExample) | ||
| EA201792565A1 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| JP2017525777A5 (enExample) | ||
| Li et al. | Complete resection of intracardiac leiomyomatosis through an abdominal approach under peripheral cardiopulmonary bypass | |
| Yasuda et al. | Left atrium ball thrombus in a patient with hemorrhagic cerebral infarction | |
| JP2013532146A5 (enExample) |